Akanda (AKAN) Total Non-Current Liabilities (2020 - 2025)
Akanda's (AKAN) quarterly Total Non-Current Liabilities came in at $12.0 million in Q4 2025, up 229.53% year-on-year from $3.6 million in Q4 2024, and up 16813.78% quarter-over-quarter from $70869.0 in Q2 2025.
Akanda (AKAN) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
Akanda's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $12.0 million for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 229.53% year-over-year to $12.0 million in Q4 2025; TTM through Dec 2025 was $12.0 million, a 229.53% increase from a year earlier, with the FY2025 full-year figure at $12.0 million, up 229.53% from the prior year.
- Total Non-Current Liabilities grew to $12.0 million in Q4 2025 per AKAN's latest filing, from $70869.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $12.0 million in Q4 2025 and bottomed at $70869.0 in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $2.5 million (2022), against an average of $3.5 million.
- Across the five-year window, Total Non-Current Liabilities tumbled 69.9% in 2021 and surged 229.53% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $2.0 million in 2021, then soared by 38.9% to $2.7 million in 2022, then fell by 9.16% to $2.5 million in 2023, then soared by 45.67% to $3.6 million in 2024, then jumped by 229.53% to $12.0 million in 2025.
- Per Business Quant, the three latest AKAN Total Non-Current Liabilities figures stand at $12.0 million (Q4 2025), $70869.0 (Q2 2025), and $3.6 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Akanda | 556,353.85 | 556,353.85 | - | 11.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.99 Mn |
| Jun 30, 2025 | 70,869.00 |
| Dec 31, 2024 | 3.64 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Jun 30, 2023 | 2.48 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Jun 30, 2022 | 2.57 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Dec 31, 2020 | 6.58 Mn |